BioCentury | Aug 10, 2015
Company News

Biotest, Abbott deal

...exercised its opt-out right under a 2011 deal and Biotest will regain worldwide rights to tregalizumab...
BioCentury | Apr 28, 2014
Clinical News

Tregalizumab: Phase II data

...moderate to severe RA who had an inadequate response to methotrexate showed that once-weekly subcutaneous BT-061...
...up to 7%. Patients received methotrexate plus placebo or once-weekly 25, 50 or 75 mg BT-061...
...in 2013. Biotest AG (Xetra:BIO), Dreieich, Germany AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: Tregalizumab ( BT-061...
BioCentury | Jan 27, 2014
Emerging Company Profile

TCF: HIV against autoimmunity

...response. Althaus said the most similar compound in development is AbbVie Inc. 's tregalizumab ( BT-061...
...a Phase II dose-finding study of tregalizumab in RA patients inadequately controlled on methotrexate , tregalizumab...
BioCentury | Jul 18, 2011
Strategy

mAbs are icing on the cake

...through Phase II testing. Biotest did its first such deal last month by partnering its BT-061...
...the polyspecific immunoglobulin to treat antibody deficiency syndromes in 4Q11. The company's lead biotherapeutic is BT-061...
...psoriasis and preclinical studies for other immune-related diseases. Biotest granted Abbott exclusive, worldwide rights to BT-061...
BioCentury | Jun 27, 2011
Finance

What to do with $101M

...€9.83 (23%) to €52.53 on Tuesday after granting Abbott Laboratories (NYSE:ABT) exclusive, worldwide rights to BT-061...
BioCentury | Jun 27, 2011
Company News

Biotest, Abbott deal

...Biotest granted Abbott exclusive, worldwide rights to develop and commercialize BT-061 , a humanized mAb against...
BioCentury | Jun 27, 2011
Finance

Highlights of weekly biotech stock moves

...€9.83 (23%) to €52.53 on Tuesday after granting Abbott Laboratories (NYSE:ABT) exclusive, worldwide rights to BT-061...
BioCentury | Jun 22, 2011
Company News

Abbott licenses anti-CD4 antibody from Biotest

...Biotest AG (Xetra:BIO) granted Abbott Laboratories (NYSE:ABT) exclusive, worldwide rights to develop and commercialize BT-061...
BioCentury | Nov 2, 2005
Financial News

Biotest raises $38.1 million

...products and diagnostics for transplantation and infectious diseases and has three MAbs in preclinical development: BT-061...
BioCentury | Oct 12, 2005
Financial News

Biotest to raise EUR 31.6 million

...products and diagnostics for transplantation and infectious diseases and has three MAbs in preclinical development: BT-061...
Items per page:
1 - 10 of 11